hydrogen has been researched along with Colonic Inertia in 22 studies
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.
dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.
Colonic Inertia: Symptom characterized by the passage of stool once a week or less.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 7.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 7.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Hydrogen excretion in breath after a bean test meal showed delayed oro-cecal transit time in children with chronic constipation with abnormal total colonic transit time." | 7.73 | Breath hydrogen test after a bean meal demonstrates delayed oro-cecal transit time in children with chronic constipation. ( de Morais, MB; Fagundes-Neto, U; Lederman, HM; Soares, AC, 2005) |
| "Two female patients aged 88 and 82 who were being treated for constipation with lactulose, developed life-threatening dilatation of the bowel." | 7.72 | [Megacolon during treatment with lactulose]. ( van Bodegraven, AA; van der Vliet, HJ, 2004) |
| "To establish normal values and assess the reproducibility of the lactulose hydrogen breath test in measuring orocaecal transit time in control subjects, and to report results in a group of patients with chronic constipation as a result of colonic inertia." | 5.07 | The lactulose hydrogen breath test as a measure of orocaecal transit time. ( Ehrenpreis, ED; Jorge, JM; Wexner, SD, 1994) |
| " A total of 231 patients with clinical hypothyroidism during the second trimester of pregnancy and 210 normal pregnant women were enrolled in the lactulose methane-hydrogen breath test." | 4.12 | Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. ( Ban, Y; Cai, Y; Hao, Y; Li, J; Ouyang, Q; Sun, Z; Wang, M; Wang, W; Wu, B; Xu, Y; Zhang, M, 2022) |
| "Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time." | 3.83 | Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. ( Adler, M; Dhingra, S; Guttermuth, C; Kasir, R; Lee, A; Zakko, P; Zakko, S, 2016) |
| "Among irritable bowel syndrome (IBS) patients, breath methane producers overwhelmingly have constipation predominance (C-IBS)." | 3.78 | Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. ( Chang, C; Deepinder, F; Gunsalus, R; Hwang, L; Kim, G; Morales, W; Pimentel, M; Weitsman, S, 2012) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 3.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Lactulose, which cannot be digested and absorbed by body, is clinically widely used to treat constipation and hepatic encephalopathy." | 3.77 | Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. ( Chen, X; Hai, Y; Sun, XJ; Zuo, Q, 2011) |
| "Hydrogen excretion in breath after a bean test meal showed delayed oro-cecal transit time in children with chronic constipation with abnormal total colonic transit time." | 3.73 | Breath hydrogen test after a bean meal demonstrates delayed oro-cecal transit time in children with chronic constipation. ( de Morais, MB; Fagundes-Neto, U; Lederman, HM; Soares, AC, 2005) |
| "We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs." | 3.72 | IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. ( Kong, Y; Park, S; Pimentel, M, 2004) |
| "Two female patients aged 88 and 82 who were being treated for constipation with lactulose, developed life-threatening dilatation of the bowel." | 3.72 | [Megacolon during treatment with lactulose]. ( van Bodegraven, AA; van der Vliet, HJ, 2004) |
| "It is well accepted that long-term administration of opioids results in a dose-related constipation." | 2.70 | Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers. ( Baranowski, J; Freye, E; Latasch, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Nalyotov, AV | 1 |
| Svistunova, NA | 1 |
| Hao, Y | 1 |
| Xu, Y | 1 |
| Ban, Y | 1 |
| Li, J | 1 |
| Wu, B | 1 |
| Ouyang, Q | 1 |
| Sun, Z | 1 |
| Zhang, M | 1 |
| Cai, Y | 1 |
| Wang, M | 1 |
| Wang, W | 1 |
| Sikander, A | 1 |
| Rana, SV | 1 |
| Sinha, SK | 1 |
| Prasad, KK | 1 |
| Arora, SK | 1 |
| Konrad, P | 1 |
| Błońska, A | 2 |
| Chojnacki, J | 1 |
| Mikulska, P | 1 |
| Mędrek-Socha, M | 1 |
| Chojnacki, C | 1 |
| Łokieć, K | 1 |
| Klupińska, G | 1 |
| Walecka-Kapica, E | 1 |
| Di Stefano, M | 1 |
| Mengoli, C | 1 |
| Bergonzi, M | 1 |
| Miceli, E | 1 |
| Pagani, E | 1 |
| Corazza, GR | 1 |
| Kasir, R | 1 |
| Zakko, S | 1 |
| Zakko, P | 1 |
| Adler, M | 1 |
| Lee, A | 1 |
| Dhingra, S | 1 |
| Guttermuth, C | 1 |
| Chen, X | 1 |
| Zuo, Q | 1 |
| Hai, Y | 1 |
| Sun, XJ | 1 |
| Kim, G | 1 |
| Deepinder, F | 1 |
| Morales, W | 1 |
| Hwang, L | 1 |
| Weitsman, S | 1 |
| Chang, C | 1 |
| Gunsalus, R | 1 |
| Pimentel, M | 2 |
| Furnari, M | 1 |
| Savarino, E | 1 |
| Bruzzone, L | 1 |
| Moscatelli, A | 1 |
| Gemignani, L | 1 |
| Giannini, EG | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Dima, G | 2 |
| Peralta, D | 2 |
| Novillo, A | 1 |
| Lasa, J | 1 |
| Besasso, H | 2 |
| Soifer, L | 1 |
| Kong, Y | 1 |
| Park, S | 1 |
| van der Vliet, HJ | 1 |
| van Bodegraven, AA | 1 |
| Soares, AC | 1 |
| Lederman, HM | 1 |
| Fagundes-Neto, U | 1 |
| de Morais, MB | 1 |
| Soifer, LO | 1 |
| Iantorno, G | 1 |
| Bustos Fernández, LM | 1 |
| Soifer, G | 1 |
| Jorge, JM | 1 |
| Wexner, SD | 1 |
| Ehrenpreis, ED | 1 |
| Turberg, Y | 1 |
| Dederding, JP | 1 |
| Yuan, CS | 1 |
| Foss, JF | 1 |
| O'Connor, M | 1 |
| Moss, J | 1 |
| Roizen, MF | 1 |
| Freye, E | 1 |
| Baranowski, J | 1 |
| Latasch, L | 1 |
| Wegener, M | 1 |
| Schaffstein, J | 1 |
| Dilger, U | 1 |
| Coenen, C | 1 |
| Wedmann, B | 1 |
| Schmidt, G | 1 |
| Camboni, G | 1 |
| Basilisco, G | 1 |
| Bozzani, A | 1 |
| Bianchi, PA | 1 |
| Vajro, P | 1 |
| Silano, G | 1 |
| Longo, D | 1 |
| Staiano, A | 1 |
| Fontanella, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
2 trials available for hydrogen and Colonic Inertia
| Article | Year |
|---|---|
The lactulose hydrogen breath test as a measure of orocaecal transit time.
Topics: Adult; Aged; Breath Tests; Chronic Disease; Constipation; Diagnosis, Differential; Female; Gastroint | 1994 |
Dose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Cecum; Codeine; Constipation; Cross-Over Studies; D | 2001 |
20 other studies available for hydrogen and Colonic Inertia
| Article | Year |
|---|---|
[Assessment of the state of the small intestine microbiota in children on a long-term dairy-free diet].
Topics: Abdominal Pain; Blind Loop Syndrome; Child; Constipation; Diarrhea; Diet; Humans; Hydrogen; Intestin | 2022 |
Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.
Topics: Apolipoproteins; Apolipoproteins B; C-Reactive Protein; Cholesterol; Constipation; Fatty Acids, None | 2022 |
Association of serotonin transporter promoter polymorphism (5-HTTLPR) with orocecal transit time in irritable bowel syndrome.
Topics: Case-Control Studies; Constipation; Diarrhea; Humans; Hydrogen; Irritable Bowel Syndrome; Lactulose; | 2022 |
[Zaburzenia czynnościowe przewodu pokarmowego u osób z przerostem bakteryjnym jelita cienkiego].
Topics: Adult; Aged; Breath Tests; Constipation; Female; Gastrointestinal Microbiome; Humans; Hydrogen; Inte | 2019 |
[Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].
Topics: Adolescent; Adult; Blind Loop Syndrome; Breath Tests; Causality; Comorbidity; Constipation; Diarrhea | 2014 |
Hydrogen breath test in patients with severe constipation: the interference of the mixing of intestinal content.
Topics: Adult; Breath Tests; Constipation; False Positive Reactions; Female; Humans; Hydrogen; Male; Young A | 2014 |
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Constipation; Diarrhea; Fema | 2016 |
Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production.
Topics: Animals; Antioxidants; Constipation; Gastrointestinal Tract; Humans; Hydrogen; Inflammatory Bowel Di | 2011 |
Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath.
Topics: Adult; Breath Tests; Constipation; DNA, Bacterial; Feces; Female; Humans; Hydrogen; Irritable Bowel | 2012 |
Reassessment of the role of methane production between irritable bowel syndrome and functional constipation.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacteria; Breath Tests; Constipation; Defec | 2012 |
[Predominance of constipation in subjects with hydrogen-consuming intestinal flora].
Topics: Adult; Aged; Bacteria; Breath Tests; Case-Control Studies; Constipation; Female; Humans; Hydrogen; I | 2012 |
IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, High Pressure Liquid; Constipation; Diarrhea; | 2004 |
[Megacolon during treatment with lactulose].
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Colon; Colonic Neoplasms; Constipation; Fatal Outcome; Fatt | 2004 |
Breath hydrogen test after a bean meal demonstrates delayed oro-cecal transit time in children with chronic constipation.
Topics: Adolescent; Breath Tests; Case-Control Studies; Child; Child, Preschool; Chronic Disease; Colon; Con | 2005 |
[Breath hydrogen levels do not predict fiber intolerance in irritable bowel syndrome with constipation].
Topics: Aged; Breath Tests; Constipation; Dietary Fiber; Female; Fermentation; Humans; Hydrogen; Irritable B | 2007 |
[Evaluation of small intestinal motility].
Topics: Breath Tests; Constipation; Diarrhea; Gastrointestinal Motility; Gastrointestinal Transit; Humans; H | 1993 |
Gut motility and transit changes in patients receiving long-term methadone maintenance.
Topics: Adult; Breath Tests; Chromatography, Gas; Constipation; Female; Gastrointestinal Motility; Gastroint | 1998 |
Gastrointestinal transit of solid-liquid meal in chronic alcoholics.
Topics: Adult; Aged; Alcoholism; Autonomic Nervous System Diseases; Breath Tests; Constipation; Diarrhea; Fe | 1991 |
Repeatability of lactulose hydrogen breath test in subjects with normal or prolonged orocecal transit.
Topics: Adult; Breath Tests; Constipation; Disaccharides; Female; Gastrointestinal Transit; Humans; Hydrogen | 1988 |
Orocoecal transit time in healthy and constipated children.
Topics: Breath Tests; Child; Child, Preschool; Chronic Disease; Constipation; Female; Food; Gastrointestinal | 1988 |